Latest action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill aims to prevent drug companies from raising medication prices too quickly or unfairly.
The problem
Patients struggle to afford medications when prices increase dramatically. High drug costs force people to choose between medicine and other necessities.
The proposal
The bill would likely limit how much drug prices can increase annually and require companies to justify large price hikes to federal regulators.
The impact
Patients may pay less for medicines. Drug companies' profits could decrease. Government spending on healthcare programs may change.
People could afford their prescriptions more easily. Fewer families would face impossible choices between medications and rent or food. Better access to treatment could improve overall health outcomes.
Medicare and Medicaid programs might spend less on drug costs. This could free up federal money for other programs or reduce deficits.
Requiring price justifications could help patients and doctors understand why costs rise. This transparency might encourage more fair pricing practices.
Elderly and low-income Americans who rely on medications would benefit most. Predictable prices help people budget for essential medicines.
Lower profits could reduce pharmaceutical companies' ability to fund research for new medicines. This might slow innovation in treating serious diseases.
Government would need new agencies or staff to review price increases. These costs might offset some savings from lower drug prices.
Price controls in the US might affect drug availability globally. Other countries could see shortages if companies prioritize markets with higher prices.
Strict price limits might discourage new companies from entering the pharmaceutical market. This could reduce competition and innovation over time.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.